This is the text extract for Approval of proposal to re-apply reference pricing across brands of risperidone and quetiapine; Contact: Notifications, browse documents here.

7 November 2011

Approval of proposal to re-apply reference pricing across brands of risperidone and quetiapine

PHARMAC has approved a proposal to re-apply reference pricing across different brands of risperidone tablets and oral liquid and across different brands of quetiapine tablets from 1 July 2012. This proposal was the subject of a consultation letter dated 23 September 2011 which can be found on PHARMAC’s website at www.pharmac.govt.nz/2011/09/23 In summary, the effect of the decisions is that:  the subsidy for the Risperdal brand of risperidone tablets and oral liquid will be reduced to the level of the subsidy for all other funded brands of risperidone tablets and oral liquid (as applicable) from 1 July 2012; and the subsidy for the Quetapel brand of quetiapine tablets will be reduced to the level of the subsidy for all other funded brands of quetiapine tablets from 1 July 2012.



If the suppliers of Risperdal (Janssen) and Quetapel (Mylan) do not reduce their prices to match the new subsidies, patients could either pay a manufacturer’s surcharge to remain on these brands or switch to any other funded brand to remain on a fully funded product. All other funded brands of risperidone (Apo-Risperidone, Dr Reddy’s Risperidone, Ridal and Risperon) and quetiapine (Dr Reddy’s Quetiapine and Seroquel) will remain fully funded. Risperidone orally-disintegrating tablets (Risperdal Quicklet) and injection (Risperdal Consta) will also remain fully funded.

Details of the decisions From 1 July 2012 the subsidy for the Risperdal brand of risperidone tablets and oral liquid will be reduced in Section B of the Pharmaceutical Schedule to the level of all other funded brands of risperidone tablets and oral liquid (as applicable) as follows (prices and subsidies expressed ex-manufacturer, excluding GST):

Chemical Risperidone Risperidone Risperidone Risperidone Risperidone Risperidone Presentation Tab 0.5 mg Tab 1 mg Tab 2 mg Tab 3 mg Tab 4 mg Oral liq 1 mg per ml Brand Risperdal Risperdal Risperdal Risperdal Risperdal Risperdal Pack size 20 60 60 60 60 30 ml Current price and subsidy $5.20 $30.77 $61.53 $92.32 $123.05 $45.92 New subsidy $1.17 $6.00 $11.00 $15.00 $20.00 $18.35

A463825 Page 1 of 2

From 1 July 2012 the subsidy for the Quetapel brand of quetiapine tablets will be reduced in Section B of the Pharmaceutical Schedule to the level of all other funded brands of quetiapine tablets as follows (ex-manufacturer, excluding GST):

Current price and subsidy $16.78 $32.59 $56.70 $95.40

Chemical Quetiapine Quetiapine Quetiapine Quetiapine

Presentation Tab 25 mg Tab 100 mg Tab 200 mg Tab 300 mg

Brand Quetapel Quetapel Quetapel Quetapel

Pack size 90 90 90 90

New subsidy $10.50 $21.00 $36.00 $60.00

Feedback received We appreciate all of the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 7 October 2011 were considered in their entirety in making a decision on the proposed changes. Responses were generally supportive of the proposal.

More information If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

A463825

Page 2 of 2